CoChat
Sign Up
Cited by 23Hyperglycemia and glycemic control in critically ill and hospitalized patientsCOVID-19 Clinical Research StudiesDiabetes Management and Research

Caring for hospitalized patients with diabetes mellitus, hyperglycemia, and COVID-19: bridging the remaining knowledge gaps

Open access
Wallia, Amisha, Prince, Grace, Touma, Emilie, El Muayed, Malek, Seley, Jane Jeffrie·2020·Current Diabetes Reports
DOI 10.1007/s11892-020-01366-0PMC PMC7690847
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE OF REVIEW: This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19. RECENT FINDINGS: It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied. Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11892-020-01366-0

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • During the coronavirus disease 2019 (COVID-19) pandemic, many institutions used CGM in ICU and non-ICU settings, with the aim of minimizing exposure time and saving personal protective equipment, under an FDA policy of enforcement discretion.

    “During the coronavirus disease 2019 (COVID-19) pandemic, many institutions used CGM in ICU and non-ICU settings, with the aim of minimizing exposure time and saving personal protective equipment, under an FDA policy of enforcement discretion (49,50).”

    From 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 (2026) · cites this paper as [49]

    Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 90

  1. [3]Muniyappa R Gubbi S COVID-19 pandemic, coronaviruses, and diabetes mellitus Am J Phys Endocrinol Metab 2020 318 E736 Ee41 PMC7191633 32228322
  2. [4]Yang JK Feng Y Yuan MY Yuan SY Fu HJ Wu BY Sun GZ Yang GR Zhang XL Wang L Xu X Xu XP Chan JCN Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS Diabet Med 2006 23 623 628 16759303
  3. [6]Apicella M Campopiano MC Mantuano M Mazoni L Coppelli A Del Prato S COVID-19 in people with diabetes: understanding the reasons for worse outcomes Lancet Diabetes Endocrinol 2020 8 782 792 32687793 PMC7367664
  4. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020. This is a population based cohort study of people with diagnosed diabetes in England. PMC7426091 32798471
  5. [8]Wu C Chen X Cai Y Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China JAMA Intern Med 2020 180 1 PMC7070509 32167524
  6. [10]Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update, 2020. Stockholm: ECDC; 2020. PMC7118344 32234119
  7. [11]Bode B Garrett V Messler J Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States J Diabetes Sci Technol 2020 14 813 32389027 PMC7673150
  8. [12]Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. PMC7243801 32444366
  9. [13]Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28:1195–9. PMC7262326 32271993
  10. [14]Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, Li Z, Shaw SF, Caparosa SL, Nau CL, Saxena T, Rieg GK, Ackerson BK, Sharp AL, Skarbinski J, Naik TK, Murali SB Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med 2020. PMC7429998 32783686
  11. [15]Bode B Garrett V Messler J McFarland R Crowe J Booth R Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States J Diabetes Sci Technol 2020 14 4 813 821 32389027 PMC7673150
  12. [16]Zhu L She ZG Cheng X Qin JJ Zhang XJ Cai J Lei F Wang H Xie J Wang W Li H Zhang P Song X Chen X Xiang M Zhang C Bai L Xiang D Chen MM Liu Y Yan Y Liu M Mao W Zou J Liu L Chen G Luo P Xiao B Zhang C Zhang Z Lu Z Wang J Lu H Xia X Wang D Liao X Peng G Ye P Yang J Yuan Y Huang X Guo J Zhang BH Li H Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes Cell Metab 2020 31 1068 1077.e3 32369736 PMC7252168
  13. [17]Cariou B Hadjadj S Wargny M Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Diabetologia 2020 63 1500 1515 32472191 PMC7256180
  14. [18]Agarwal S Schechter C Southern W Crandall JP Tomer Y Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease Diabetes Care 2019 43 2020 PMC7510015 32769128
  15. [19]Chen Y Yang D Cheng B Chen J Peng A Yang C Liu C Xiong M Deng A Zhang Y Zheng L Huang K Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication Diabetes Care 2020 43 1399 1407 32409498
  16. [20]Wang S Ma P Zhang S Song S Wang Z Ma Y Xu J Wu F Duan L Yin Z Luo H Xiong N Xu M Zeng T Jin Y Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study Diabetologia 2020 63 2102 2111 32647915 PMC7347402
  17. [21]Kim NYHE Moon JS Lee YH C EU Acute hyperglycemic crises with coronavirus disease-19: case reports Diabetes Metab J 2020 44 349 353 32347027 PMC7188962
  18. [22]Jie Chee Y, Jia Huey Ng S, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020:108166, 164. PMC7194589 32339533
  19. [23]Palermo NE Sadhu AR McDonnell ME Diabetic ketoacidosis in COVID-19: unique concerns and considerations J Clin Endocrinol Metab 2020 105 2819 2829 PMC7337869 32556147
  20. [24]Bornstein SR Rubino F Khunti K Practical recommendations for the management of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol 2020 8 546 32334646 PMC7180013
  21. [25]Pal R Banerjee M Yadav U Bhattacharjee S Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature Diabetes Metab Syndr 2020 14 1563 1569 32853901 PMC7434433
  22. [26]Gianchandani R Esfandiari NH Ang L Iyengar J Knotts S Choksi P Pop-Busui R Managing hyperglycemia in the COVID-19 inflammatory storm Diabetes 2020 69 2048 2053 32778570
  23. [27]Le Roith D Diabetes mellitus: a fundamental and clinical text 2003 3 Philadelphia Lippincott Williams & Wilkins
  24. [28]Ovalle F Clinical approach to the patient with diabetes mellitus and very high insulin requirements Diabetes Res Clin Pract 2010 90 231 242 20724017
  25. [29]Illuri VD Layden BT Aleppo G Extreme insulin resistance in critically ill patient with sepsis Clin Diabetes 2016 34 158 160 27621533 PMC5019008
  26. [30]Ettleson MD Arguello V Wallia A Arguelles L Bernstein RA Molitch ME Hyperglycemia and insulin resistance in cardiac arrest patients treated with moderate hypothermia J Clin Endocrinol Metab 2014 99 E2010 E2014 25033067
  27. [32]Oo YH Karam JG Resta CA Extreme insulin resistance in a patient with diabetes ketoacidosis and acute myocardial infarction Case Rep Endocrinol 2013 2013 520904 23424687 PMC3568915
  28. [33]Donath MY Storling J Berchtold LA Billestrup N Mandrup-Poulsen T Cytokines and beta-cell biology: from concept to clinical translation Endocr Rev 2008 29 334 350 18048762
  29. [34]Pilla SJ Quan AQ Germain-Lee EL Hellmann DB Mathioudakis NN Immune-modulating therapy for rheumatologic disease: implications for patients with diabetes Curr Diab Rep 2016 16 91 27525682 PMC6031126
  30. [35]Winter EM, Schrander-van der Meer A, Eustatia-Rutten C, Janssen M. Hydroxychloroquine as a glucose lowering drug. BMJ Case Rep. 2011;bcr0620114393. PMC3207745 22675089
  31. [36]Filippi CM von Herrath MG Viral trigger for type 1 diabetes: pros and cons Diabetes 2008 57 2863 2871 18971433 PMC2570378
  32. [37]Hyoty H Taylor KW The role of viruses in human diabetes Diabetologia 2002 45 1353 1361 12378375
  33. [38]Roivainen M Enteroviruses: new findings on the role of enteroviruses in type 1 diabetes Int J Biochem Cell Biol 2006 38 721 725 16226050
  34. [39]Honeyman MC Stone NL Harrison LC T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents Mol Med 1998 4 231 239 9606176 PMC2230363
  35. [40]Honeyman MC Coulson BS Stone NL Gellert SA Goldwater PN Steele CE Couper JJ Tait BD Colman PG Harrison LC Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes Diabetes 2000 49 1319 1324 10923632
  36. [41]Sjoholm A Ketosis-prone type 2 diabetes: a case series Front Endocrinol 2019 10 684 PMC6843078 31749761
  37. [42]Balasubramanyam A Nalini R Hampe CS Maldonado M Syndromes of ketosis-prone diabetes mellitus Endocr Rev 2008 29 292 302 18292467 PMC2528854
  38. [43]Yang JK Lin SS Ji XJ Guo LM Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Acta Diabetol 2010 47 193 199 19333547 PMC7088164
  39. [44]Liu F Long X Zhang B Zhang W Chen X Zhang Z ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection Clin Gastroenterol Hepatol 2020 18 2128 2130.e2 32334082 PMC7194639
  40. [45]Tikellis C Wookey PJ Candido R Andrikopoulos S Thomas MC Cooper ME Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat Diabetes 2004 53 989 997 15047614
  41. [46]Hoffmann M Kleine-Weber H Schroeder S SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 2020 181 271 80.e8 32142651 PMC7102627
  42. [47]Huang C Wang Y Li X Ren L Zhao J Hu Y Zhang L Fan G Xu J Gu X Cheng Z Yu T Xia J Wei Y Wu W Xie X Yin W Li H Liu M Xiao Y Gao H Guo L Xie J Wang G Jiang R Gao Z Jin Q Wang J Cao B Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020 395 497 506 31986264 PMC7159299
  43. [48]Young BE Ong SWX Kalimuddin S Low JG Tan SY Loh J Ng OT Marimuthu K Ang LW Mak TM Lau SK Anderson DE Chan KS Tan TY Ng TY Cui L Said Z Kurupatham L Chen MIC Chan M Vasoo S Wang LF Tan BH Lin RTP Lee VJM Leo YS Lye DC for the Singapore 2019 Novel Coronavirus Outbreak Research Team Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Jama 2020 323 1488 1494 32125362 PMC7054855
  44. [49]Lecube A Hernandez C Genesca J Simo R Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis Diabetes Care 2006 29 1140 1149 16644655
  45. [50]Venetsanaki V Boutis A Chrisoulidou A Papakotoulas P Diabetes mellitus secondary to treatment with immune checkpoint inhibitors Curr Oncol 2019 26 e111 e1e4 30853817 PMC6380640
  46. [51]Uhteg K Jarrett J Richards M Howard C Morehead E Geahr M Gluck L Hanlon A Ellis B Kaur H Simner P Carroll KC Mostafa HH Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays J Clin Virol 2020 127 104384 32361285 PMC7194987
  47. [52]Ai T Yang Z Hou H Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases Radiology 2020 296 2 E32 E40 32101510 PMC7233399
  48. [53]Hanson K, Caliendo A, Arias C, Englund J, Lee M, Loeb M, et al. Infectious Disease Society of America Guidelines on the Diagnosis of COVID-19. Clin Infect Dis. 2020;ciaa760. PMC7337674 32556191
  49. [55]Sardu C D'Onofrio N Balestrieri ML Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 2020 43 1408 1415 32430456 PMC7305003
  50. [56]15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S193–202. 31862758
  51. [57]Van den Berghe G Wilmer A Hermans G Intensive insulin therapy in the medical ICU N Engl J Med 2006 354 449 461 16452557
  52. [58]van den Berghe G Wouters P Weekers F Verwaest C Bruyninckx F Schetz M Vlasselaers D Ferdinande P Lauwers P Bouillon R Intensive insulin therapy in critically ill patients N Engl J Med 2001 345 1359 1367 11794168
  53. [59]Kumar S Molitch ME Use of insulin in the inpatient setting: need for continued use Curr Diab Rep 2019 19 64 31346798
  54. [60]Langouche L Vanhorebeek I Vlasselaers D Vander Perre S Wouters PJ Skogstrand K Hansen TK van den Berghe G Intensive insulin therapy protects the endothelium of critically ill patients J Clin Invest 2005 115 2277 2286 16075063 PMC1180545
  55. [61]Vanhorebeek I Langouche L Van den Berghe G Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr Opin Crit Care 2005 11 304 311 16015107
  56. [62]Wallia A Schmidt K Johnson Oakes D Pollack T Welsh N Kling-Colson S Glycemic control reduces infections in post-liver transplant patients: results of a prospective, randomized study J Clin Endocrinol Metab 2017 102 2 451 459 27875061 PMC6283442
  57. [63]Andersen SK Gjedsted J Christiansen C Tonnesen E The roles of insulin and hyperglycemia in sepsis pathogenesis J Leukoc Biol 2004 75 413 421 14657207
  58. [64]Deng HP Chai JK The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis Int Immunopharmacol 2009 9 1251 1259 19647101
  59. [65]Iacobellis G COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract 2020 162 108125 32224164 PMC7271223
  60. [66]Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41. PMC7184382 32294179
  61. Korytkowski M Antinori-Lent K Drincic A Hirsch I McDonnell M Rushakoff R A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic J Clin Endocrinol Metab 2020 105 9 dgaa342 32498085 PMC7313952
  62. [69]Pasquel FJ Fayfman M Umpierrez GE Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes? Curr Diab Rep 2019 19 65 31353426
  63. [70]Lorenzo-Gonzalez C Atienza-Sanchez E Reyes-Umpierrez D Safety and efficacy of ddp4-inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes Endocrine Pract 2020 26 722 728 PMC11305855 33471640
  64. [71]Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis Jama 2007 298 194 206 17622601
  65. [72]Mikhail N Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes Curr Drug Saf 2011 6 304 309 22424537
  66. [73]Willemen MJ Mantel-Teeuwisse AK Straus SM Meyboom RH Egberts TC Leufkens HG Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase Diabetes Care 2011 34 369 374 21270195 PMC3024351
  67. [74]Mulvihill EE Drucker DJ Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr Rev 2014 35 992 1019 25216328 PMC7108477
  68. [77]Xu J Wang J He M Han H Xie W Wang H Kong H Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension Lab Investig 2018 98 1333 1346 29789684
  69. [78]Meyerholz DK Lambertz AM McCray PB Jr Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome Am J Pathol 2016 186 78 86 26597880 PMC4715219
  70. [79]Schnapp G Klein T Hoevels Y Bakker RA Nar H Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure J Med Chem 2016 59 7466 7477 27438064
  71. [80]Reichetzeder C von Websky K Tsuprykov O Mohagheghi Samarin A Falke LG Dwi Putra SE Hasan AA Antonenko V Curato C Rippmann J Klein T Hocher B Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury Br J Pharmacol 2017 174 2273 2286 28423178 PMC5481645
  72. [81]Resar R Pronovost P Haraden C Simmonds T Rainey T Nolan T Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia Jt Comm J Qual Patient Saf 2005 31 243 248 15960014
  73. [83]Schwartz J King CC Yen MY Protecting health care workers during the COVID-19 coronavirus outbreak -lessons from Taiwan’s SARS response Clin Infect Dis 2020 53 363 PMC7108122 32166318
  74. [84]Yen MY Lin YE Lee CH Ho MS Huang FY Chang SC Liu YC Taiwan’s traffic control bundle and the elimination of nosocomial severe acute respiratory syndrome among healthcare workers J Hospital Infection 2011 77 332 337 PMC7114589 21316802
  75. [85]Jones MS Goley AL Alexander BE Keller SB Caldwell MM Buse JB Inpatient transition to virtual care during COVID-19 pandemic Diabetes Technol Ther 2020 22 444 448 32396395 PMC7262638
  76. [90]Umpierrez GE Cuervo R Karabell A Latif K Freire AX Kitabchi AE Treatment of diabetic ketoacidosis with subcutaneous insulin aspart Diabetes Care 2004 27 1873 1878 15277410
  77. [93]Wallia A Umpierrez GE Rushakoff RJ Klonoff DC Rubin DJ Hill Golden S Cook CB Thompson B the DTS Continuous Glucose Monitoring in the Hospital Panel Consensus statement on inpatient use of continuous glucose monitoring J Diabetes Sci Technol 2017 11 1036 1044 28429611 PMC5950996
  78. [94]Shehav-Zaltzman G Segal G Konvalina N Tirosh A Remote glucose monitoring of hospitalized, quarantined patients with diabetes and COVID-19 Diabetes Care 2020 43 e75 ee6 32409500 PMC7305009
  79. [96]Reutrakul S, Genco M, Salinas H, et al. Feasibility of inpatient continuous glucose monitoring during the COVID-19 pandemic: early experience. Diabetes Care. 2020. PMC7876554 32769129
  80. [98]•• Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. Diabetes Care. 2020;43:2873. This is a randomized controlled trial of real-time continuous glucose monitoring compared to point of care in a non-ICU community hospital setting. PMC7576427 32855160
  81. [100]Meyers DC Durlak JA Wandersman A The quality implementation framework: a synthesis of critical steps in the implementation process Am J Community Psychol 2012 50 462 480 22644083
  82. [102]Hoffman T, Nissen K, Krambrich J. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. 2020;10:1754538. PMC7178815 32363011
  83. [104]Dungan KM Braithwaite SS Preiser JC Stress hyperglycaemia Lancet 2009 373 1798 1807 19465235 PMC3144755
  84. [105]Wang XL Zhang L Youker K Zhang MX Wang J LeMaire SA Coselli JS Shen YH Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase Diabetes 2006 55 2301 2310 16873694
  85. [107]Ansorge S Bank U Heimburg A Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions Clin Chem Lab Med 2009 47 253 261 19327105
  86. [109]Noble JA Valdes AM Genetics of the HLA region in the prediction of type 1 diabetes Curr Diab Rep 2011 11 533 542 21912932 PMC3233362
  87. [111]Lehmann-Werman R Neiman D Zemmour H Moss J Magenheim J Vaknin-Dembinsky A Rubertsson S Nellgård B Blennow K Zetterberg H Spalding K Haller MJ Wasserfall CH Schatz DA Greenbaum CJ Dorrell C Grompe M Zick A Hubert A Maoz M Fendrich V Bartsch DK Golan T Ben Sasson SA Zamir G Razin A Cedar H Shapiro AMJ Glaser B Shemer R Dor Y Identification of tissue-specific cell death using methylation patterns of circulating DNA Proc Natl Acad Sci U S A 2016 113 E1826 E1834 26976580 PMC4822610
  88. [112]Gala-Lopez BL Neiman D Kin T Beta cell death by cell-free DNA and outcome after clinical islet transplantation Transplantation 2018 102 978 985 29329189
  89. [113]Tersey SA, Nelson JB, Fisher MM, Mirmira RG. Measurement of differentially methylated INS DNA species in human serum samples as a biomarker of islet beta cell death. J Vis Exp. 2016;(118):54838. 10.3791/54838. PMC5226430 28060259 · DOI
  90. [114]Naylor R Knight Johnson A del Gaudio D Adam MP Ardinger HH Pagon RA Maturity-onset diabetes of the young overview GeneReviews((R)) 1993 Seattle University of Washington, Seattle. University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle 29792621

Cited by

Sorted by citations

Authors
Wallia, A., Prince, G., Touma, E., El Muayed, M., & Seley, J. J.
Affiliations
  • Northwestern University (US)
  • Weill Cornell Medicine (US)
Corresponding author
Wallia, Amisha
ORCID
Venue
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Published
2020-11-26
Volume
20
Issue
12
Pages
77-77
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
DOI
10.1007/s11892-020-01366-0
PMC
PMC7690847
OpenAlex
W3106764176
Cited by
23
References
13
Citations by year
2025: 1 · 2024: 4 · 2023: 7 · 2022: 8 · 2021: 3
FWCI
0.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Diabetes Reports (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Environmental Health Sciences (R01ES027011)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
COVID-19 pandemic, SARS-CoV-2, diabetes mellitus, hyperglycemia, hospitalized patients, insulin resistance, beta-cell dysfunction, diabetic ketoacidosis, glycemic control, inpatient diabetes management, healthcare worker safety, pandemic
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Diabetes Mellitus, Humans, Hyperglycemia, Pneumonia, Viral, Coronavirus Infections, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review